NORTHSIDE HOSPITAL CANCER INSTITUTE

BLOOD & MARROW TRANSPLANT PROGRAM

The Blood & Marrow Transplant Group OF GEORGIA

NORTHSIDE HOSPITAL CANCER INSTITUTE

LEUKEMIA PROGRAM



Blood and Marrow Transplant Program

Clinical Trial Opening

Open to Enrollment: Phase 2 Randomized Open-label Study of MEDI-551 in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NSH-BMT, in collaboration with Medimmune, is offering an investigational clinical trial for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL)

MEDI-551 is a humanized IgG1κMAb directed against human CD 19. The broad expression profile of CD19 on B-cell malignancies such as NHL makes CD19 an attractive target for patients in whom first-line therapy with rituximab has failed. MEDI-551, which targets CD19, appears to be safe and has shown activity in patients with B-cell malignancies whose disease has progressed while on therapy with rituximab.

The primary objective of this study is to evaluate the overall response rate (ORR), including partial response (PR) and complete response (CR), of subjects treated with MEDI-551 when used in combination with a chemotherapy regimen containing either ICE or DHAP versus rituximab in combination with ICE or DHAP in subjects with relapsed or refractory diffuse large B-cell Lymphoma.

To be considered for this study, patients must meet the following criteria:

1. Age 18+
2. Histologically confirmed aggressive B-cell DLBCL, including follicular lymphoma transforming to DLBCL and Grade IIIa and Grade IIIb.
3. Willing to provide some or all of archived DLBCL tumor sample if a sufficient sample quantity is available.
4. Computed tomography scans showing involvement of 1 or more clearly demarcated lesions measuring at least 1.5 cm.
5. Baseline PET or PET/CT scans must demonstrate positive lesions compatible with CT-defined anatomical tumor sites.
6. Relapsed from or refractory to at least one chemotherapy regimen containing rituximab
7. Eligible for autologous stem cell transplant

If you have any questions, would like to discuss study logistics, or the eligibility of any patients, please contact Stacey Brown, NSH BMT/Leukemia Clinical Research Manager, at 404-851-8238 or stacey.brown@northside.com